FAP and neoplasm: Although imaging of FAP showed great promise in both preclinical studies and clinical trials, the therapeutic efficacy of the fibroblast activation protein inhibitor alone is still limited due to a relatively short retention time of the corresponding radiopharmaceuticals in the tumor area.